DoW Breast Cancer, Clinical Research Extension Award | Apply Online

FAQs: FY26 DoD Breast Cancer Research Program (BCRP) Clinical Research Extension Award

What is the FY26 DoD BCRP Clinical Research Extension Award designed to fund?

This award is designed to extend and strengthen existing breast cancer clinical research rather than start brand-new clinical trials. It supports efforts that increase the value of studies that are already underway or were previously launched, especially where more follow-up, more complete data collection, or deeper analysis could produce clinically meaningful insights.

Does this opportunity fund new clinical trials?

Based on the provided description, the mechanism is not intended to fund brand-new clinical trials. Instead, it focuses on building on existing clinical studies through activities like added data collection, longer patient follow-up, and more complete analysis of existing datasets and specimens.

What kinds of activities are considered a good fit for this award?

The opportunity emphasizes extensions that help extract additional clinical value from existing studies, including:

• Added data collection to address gaps from the original study
• Longer-term patient follow-up to capture outcomes that require more time
• Deeper, more complete analysis of existing clinical datasets
• Additional work with existing specimens and biospecimens that were collected but not fully analyzed

Why is the program focused on extending existing studies?

The stated goal is to prevent important clinical insights from being lost when trials end early, when follow-up is too short to observe meaningful outcomes, or when data/specimen collection was incomplete or not fully analyzed. The broader intent is to translate past patient participation into stronger evidence that can better inform care, survivorship, and future research.

Do applications have to address specific FY26 BCRP overarching challenges?

Yes. Every application must directly address at least one FY26 BCRP overarching challenge unless the applicant provides a strong, well-supported justification for an exception. Even though the specific challenges are not listed in the provided text, the key expectation is clear alignment with the program's current priority problem areas rather than only general breast cancer research aims.

What happens if a proposal does not align with the FY26 BCRP overarching challenges?

Proposals that do not align with at least one overarching challenge (and also do not convincingly justify an exception) risk being viewed as nonresponsive. Nonresponsive applications are more likely to be excluded or disadvantaged in review.

Are consumer advocates required on the research team?

Yes. The research team must include at least two breast cancer consumer advocates. The requirement is presented as a meaningful program feature, signaling that patient and survivor perspectives are expected to be integrated into study planning, interpretation, and the practical relevance of outcomes.

Is the consumer advocate role intended to be substantive or symbolic?

The description indicates it is not a token role. The program expects the advocates to contribute in meaningful ways to the project, including helping shape planning decisions, interpreting results, and keeping the study outcomes aligned with patient and survivor priorities.

What PI leadership models are allowed under this award?

The mechanism allows either:

• A single Principal Investigator (PI) model, or
• A two-PI partnering model with an Initiating PI and a Partnering PI

How does the Partnering PI Option (PPIO) work at the pre-application stage?

Under the Partnering PI Option, only the Initiating PI submits the pre-application. This means the initial submission responsibility sits with the Initiating PI at that stage.

What is required at the full application stage under the Partnering PI Option (PPIO)?

At the full application stage, both the Initiating PI submission and the Partnering PI submission must be completed. The opportunity description highlights that if either associated submission is missing by the deadline, the application can be administratively withdrawn.

What is the main administrative risk to watch for with the two-PI partnering model?

The main risk described is coordination failure: if the Initiating PI and Partnering PI do not both complete their required full-application submissions by the deadline, the application may be administratively withdrawn. Timeline planning and cross-team coordination are critical.

Who runs this grant opportunity?

It is a discretionary grant opportunity run through the Defense Health Agency Contracting Activity (DHACA) as part of the DoD Breast Cancer Research Program (BCRP).

What is the opportunity number?

The opportunity number is HT942526BCRPCREA2.

What is the CFDA number for this opportunity?

The CFDA number listed is 12.420.

What category is this funding listed under?

The listing identifies the category as Science and Technology / Research and Development.

What is the closing date shown for this opportunity?

The posted closing date is 2026-11-18.

How many awards are expected?

The listing notes an expected number of awards as 1. That implies extremely limited availability and a highly competitive environment.

Is eligibility limited to certain institution types?

Eligibility is described as "unrestricted" in the provided information, suggesting a broad applicant pool may be permitted. However, the excerpt also implies that standard DoD and program-specific requirements may still apply and would need to be confirmed in the full announcement.

Is there an award ceiling or budget limit listed in the provided details?

No. The award ceiling is not stated in the provided text. Applicants would need to consult the full announcement to confirm budget limits, allowable costs, and the expected project period.

What is the central purpose of this award in practical terms?

The award is meant to extend the scientific and clinical payoff of breast cancer clinical research that is already underway or previously initiated. It targets common situations where important outcomes might be missed due to short follow-up, incomplete data capture, incomplete biospecimen work, or analysis that was not fully pursued.

What outcomes does the program appear to prioritize?

The description emphasizes clinically relevant outcomes and producing stronger evidence that can inform care and survivorship, while also guiding future research. The structure requiring consumer advocates reinforces a focus on practical relevance to patients and survivors.